FDMT (STOCKS)
4D Molecular Therapeutics, Inc. Common Stock
$9.370000
+0.540000 (+6.12%)
Prev close: $8.830000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David H. Kirn
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $489.83M
- Employees
- 227
- P/E (TTM)
- -3.31
- P/B (TTM)
- 1.02
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.01 | $-1.01 | +0.0021 | +0.21% |
|
Dec 2025 (Q4)
|
$0.43 | $-0.78 | +1.2077 | +155.29% |
|
Sep 2025 (Q3)
|
$-1.01 | $-1.00 | -0.0118 | -1.18% |
|
Jun 2025 (Q2)
|
$-0.98 | $-0.89 | -0.0867 | -9.71% |
Financial Statements
| Revenues | $88.24M |
| Benefits Costs and Expenses | $137.50M |
| Costs And Expenses | $258.25M |
| Nonoperating Income/Loss | $18.65M |
| Operating Expenses | $267.79M |
| Depreciation and Amortization | $4.91M |
| Other Operating Expenses | $262.88M |
| Operating Income/Loss | -$179.55M |
| Income/Loss From Continuing Operations After Tax | -$160.90M |
| Income/Loss From Continuing Operations Before Tax | -$103.93M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$160.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$160.90M |
| Net Income/Loss Available To Common Stockholders, Basic | -$160.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.57 |
| Diluted Earnings Per Share | -$2.57 |
| Basic Average Shares | 182,114,297 |
| Diluted Average Shares | 182,114,297 |
| Assets | $512.91M |
| Current Assets | $405.36M |
| Noncurrent Assets | $107.54M |
| Fixed Assets | $13.59M |
| Other Non-current Assets | $93.95M |
| Liabilities | $61.07M |
| Current Liabilities | $43.40M |
| Accounts Payable | $14.69M |
| Wages | $6.24M |
| Other Current Liabilities | $22.47M |
| Noncurrent Liabilities | $17.67M |
| Equity | $451.84M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $451.84M |
| Liabilities And Equity | $512.91M |
| Net Cash Flow From Operating Activities | -$129.45M |
| Net Cash Flow From Operating Activities, Continuing | -$129.45M |
| Net Cash Flow From Investing Activities | -$56.03M |
| Net Cash Flow From Investing Activities, Continuing | -$56.03M |
| Net Cash Flow From Financing Activities | $108.63M |
| Net Cash Flow From Financing Activities, Continuing | $108.63M |
| Net Cash Flow | -$76.85M |
| Net Cash Flow, Continuing | -$76.85M |
| Comprehensive Income/Loss | -$161.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$161.41M |
| Other Comprehensive Income/Loss | -$57.39M |